Show simple item record

dc.contributor.authorGu, W
dc.contributor.authorPayne, E
dc.contributor.authorSun, S
dc.contributor.authorBurgess, M
dc.contributor.authorMcMillan, NAJ
dc.date.accessioned2017-05-03T13:12:31Z
dc.date.available2017-05-03T13:12:31Z
dc.date.issued2011
dc.date.modified2012-05-29T22:21:29Z
dc.identifier.issn0929-1903
dc.identifier.doi10.1038/cgt.2010.72
dc.identifier.urihttp://hdl.handle.net/10072/44374
dc.description.abstractRNA interference (RNAi)-based gene silencing is widely used in laboratories for gene function studies and also holds a great promise for developing treatments for diseases. However, in vivo delivery of RNAi therapy remains a key issue. Lentiviral vectors have been employed for stable gene transfer and gene therapy and therefore are expected to deliver a stable and durable RNAi therapy. But this does not seem to be true in some disease models. Here, we showed that lentivirus delivered short-hairpin RNA (shRNA) against human papillomavirus (HPV) E6/E7 oncogenes were effective for only 2 weeks in a cervical cancer model. However, using this vector to carry two copies of the same shRNA or two shRNAs targeting at two different but closely related genes (HPV E6 and vascular endothelial growth factor) was more effective at silencing the gene targets and inhibiting cell or even tumor growth than their single shRNA counterparts. The cancer cells treated with dual shRNA were also more sensitive to chemotherapeutic drugs than single shRNA-treated cells. These results suggest that a multi-shRNA strategy may be a more attractive approach for developing an RNAi therapy for this cancer.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent361856 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherNature Publishing Group
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom219
dc.relation.ispartofpageto227
dc.relation.ispartofjournalCancer Gene Therapy: the journal of cancer gene and cellular therapies
dc.relation.ispartofvolume18
dc.rights.retentionY
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchOncology and carcinogenesis not elsewhere classified
dc.subject.fieldofresearchcode3211
dc.subject.fieldofresearchcode321199
dc.titleInhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2011 Nature Publishing Group. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
gro.date.issued2011
gro.hasfulltextFull Text
gro.griffith.authorMcMillan, Nigel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record